These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9512763)

  • 1. Adverse effects of cytotoxics-platinum agents.
    Selvaratnam G; Philips RH; Mohamed AK; Radzi A
    Adverse Drug React Toxicol Rev; 1997 Aug; 16(3):171-97. PubMed ID: 9512763
    [No Abstract]   [Full Text] [Related]  

  • 2. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
    Hayek M; Srinivasan A
    Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
    [No Abstract]   [Full Text] [Related]  

  • 3. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
    Ali BH; Al Moundhri MS
    Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention and treatment of the side effects of cancer chemotherapy].
    Iki S; Urabe A
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1635-40. PubMed ID: 11057312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [About side effects of platinum drugs].
    Waszkiewicz K
    Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G; Belani CP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
    Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
    Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of the cytoprotectant amifostine.
    Lindemann K
    Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurochemistry of the peripheral and central auditory system after ototoxic drug exposure: implications for tinnitus.
    Rybak LP
    Int Tinnitus J; 2005; 11(1):23-30. PubMed ID: 16419684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Amifostin in protection of kidney from cisplatinum injury].
    Cui H; Zhang S; Li P; Guan Z; Sun X; Shen K; Wu M; Hu X; Liu S; Di L; Zhang S
    Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):48-50. PubMed ID: 11977638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
    Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.
    Cronin S; Uberti JP; Ayash LJ; Raith C; Ratanatharathorn V
    Bone Marrow Transplant; 2000 Dec; 26(11):1247-9. PubMed ID: 11149742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin nephrotoxicity affects magnesium and calcium metabolism.
    Goren MP
    Med Pediatr Oncol; 2003 Sep; 41(3):186-9. PubMed ID: 12868117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
    Korst AE; van der Sterre ML; Eeltink CM; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
    Clin Cancer Res; 1997 May; 3(5):697-703. PubMed ID: 9815738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future directions in gynecologic cancer.
    Alberts DS
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):125-8. PubMed ID: 10348271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
    Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
    Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S; Chewaskulyong B
    J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxicity from chemotherapy: prevention and management.
    Vogelzang NJ
    Oncology (Williston Park); 1991 Oct; 5(10):97-102, 105; disc. 105, 109-11. PubMed ID: 1838278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity.
    Bianchi R; Brines M; Lauria G; Savino C; Gilardini A; Nicolini G; Rodriguez-Menendez V; Oggioni N; Canta A; Penza P; Lombardi R; Minoia C; Ronchi A; Cerami A; Ghezzi P; Cavaletti G
    Clin Cancer Res; 2006 Apr; 12(8):2607-12. PubMed ID: 16638873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.